Adegbamigbe Oluwafemi Johanson, Adewuyi James Olabanji, Olatunji Philip O
Department of Haematology, Federal Medical Centre, Ido-Ekiti, Nigeria.
Department of Haematology, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
Niger Med J. 2014 Sep;55(5):374-8. doi: 10.4103/0300-1652.140324.
The initiation of antiretroviral (ARV) drugs and monitoring of human immunodeficiency virus (HIV) treatment in developing nations such as sub-Sahara Africa is based on the clinical stage and level of CD4 count. Clinical stages can easily be determined using the World Health Organisation (WHO) criteria, this is not so with CD4 count where the right equipment and expertise are not easily available. This lead to various studies being carried out in search of surrogates for CD4 count with use of total lymphocyte count (TLC) being suggested by some studies.
In situation where determination of CD4 cell count is not available or feasible, lymphocyte count is believed to be one alternative method for immunological classification of Acquired Immunodeficiency Syndrome (AIDS). Such assumption may not be true of every population. The objective is, therefore, to examine the correlation between the absolute lymphocyte count and the CD4+ lymphocyte count in HIV positive patients.
One hundred and sixty-five consecutive HIV positive patients were recruited for the study before the commencement of ARV drugs over a period of 13 months. The haemotological parameters such as the CD4 count was done by flow cytometry using Partec cyflow counter machine made in Germany, with strict adherence to the manufacturer's standard operating procedure. TLC were also determined using Sysmex haematology blood analyser, following the manufacturer's standard operating procedure. Patients were then grouped into CD4 and Total lymphocyte (TLC) categories. These were then compared to determine if there is any correlation as shown in previous studies. Statistical analysis of data was done using Statistical Package for Social Sciences (SPSS) and statistical significance of data was based on P value of less than 0.05. There was significant positive correlation (P value 0.000) between TLC and CD4 count.
Majority of the patients with TLC less than 1000/mm([3]) had CD4 count <200 cells/μl. Using TLC <1000/mm([3]) threshold, there was high sensitivity of 81.8% but low specificity and positive predictive value of 47.5% and 19.4%, respectively, for CD4 count <200 cells/μl. Further assessment using TLC of <1,200/mm([3]) for the currently accepted CD4 count cut-off of <350 cells/μl for initiation of antiretroviral drugs, the sensitivity, specificity, positive predictive value were found to be 76.5%, 26.7%, 21.3%, respectively.
Considering the low specificity and positive predictive value, it was concluded that the use of TLC of as a surrogate for CD4 count is unreliable. However, where there is no alternative, it could be used with caution bearing in mind its limitations.
在撒哈拉以南非洲等发展中国家,抗逆转录病毒(ARV)药物的起始使用及人类免疫缺陷病毒(HIV)治疗的监测是基于临床分期和CD4细胞计数水平。临床分期可轻松依据世界卫生组织(WHO)标准确定,但CD4细胞计数并非如此,因为不易获得合适的设备和专业技术。这导致开展了各种研究以寻找CD4细胞计数的替代指标,一些研究建议使用总淋巴细胞计数(TLC)。
在无法或不可行测定CD4细胞计数的情况下,淋巴细胞计数被认为是对获得性免疫缺陷综合征(AIDS)进行免疫分类的一种替代方法。然而,这种假设可能并非对所有人群都成立。因此,目的是研究HIV阳性患者的绝对淋巴细胞计数与CD4 +淋巴细胞计数之间的相关性。
在13个月的时间里,连续招募了165例HIV阳性患者,在开始使用ARV药物之前进行研究。血液学参数如CD4细胞计数通过使用德国制造的Partec cyflow计数仪的流式细胞术进行测定,严格遵循制造商的标准操作程序。TLC也使用Sysmex血液分析仪按照制造商的标准操作程序进行测定。然后将患者分为CD4和总淋巴细胞(TLC)类别。接着对这些类别进行比较,以确定是否存在如先前研究所显示的任何相关性。使用社会科学统计软件包(SPSS)对数据进行统计分析,数据的统计学显著性基于P值小于0.05。TLC与CD4细胞计数之间存在显著正相关(P值0.000)。
大多数TLC低于1000/mm³的患者CD4细胞计数<200个/μl。使用TLC<1000/mm³的阈值,对于CD4细胞计数<200个/μl,敏感性高达81.8%,但特异性和阳性预测值分别低至47.5%和19.4%。对于目前接受的启动抗逆转录病毒药物的CD4细胞计数临界值<350个/μl,使用TLC<1200/mm³进行进一步评估,发现敏感性、特异性、阳性预测值分别为76.5%、26.7%、21.3%。
考虑到低特异性和阳性预测值,得出结论:使用TLC作为CD4细胞计数的替代指标是不可靠的。然而,在没有其他选择的情况下,可以谨慎使用,同时要牢记其局限性。